Giving Vaccines the Boost They Need

By Dr Deirdre Gillespie, President and Chief Executive Officer at Oxxon PharmaccinesTM Ltd

Dr Deirdre Gillespie is President and Chief Executive Officer of Oxxon PharmaccinesTM Ltd, a biotechnology company developing innovative immunotherapeutics, specifically therapeutic vaccines (pharmaccines), for the treatment of chronic infectious diseases and cancer. While at Oxxon, Deirdre has overseen the progression of the company's pharmaccines for the treatment of Hepatitis B and malignant melanoma into Phase II clinical trials.

Deirdre was also instrumental in a recently announced private financing that saw Oxxon raise £15 million in an international funding round. She has 16 years' experience in the pharmaceutical and biotechnology industries including senior positions at Vical Inc and DuPont Merck Pharmaceutical Company. Deirdre gained a medical degree from London University and an MBA from London Business School.